Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05444283 · ClinicalTrials.gov registry record
Genomic Predictors of Recurrent Pregnancy Loss
A clinical trial of Recurrent Pregnancy Loss, sponsored by Yale University.
- Recruiting
- Registry status
- 500
- Enrollment target
- 10
- Study locations
NCT05444283: Recruiting study of Recurrent Pregnancy Loss, sponsored by Yale University.
NCT05444283 is a study of Recurrent Pregnancy Loss that is actively recruiting participants, run by Yale University. The registered enrollment target is 500 participants. The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05444283, a study of Recurrent Pregnancy Loss, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 10
- Study locations
Study Summary
The overall goals of this proposal are to determine the genetic architecture of recurrent pregnancy loss (RPL) and to discover genomic predictors of RPL.
Primary Outcome
The WGS tool will be used to analyze the POC sample and parental blood samples to determine the clinical reportable genetic cause for RPL
Conditions Studied
Study Locations (10)
Illinois
- Northwestern University - Chicago
- University of Chicago - Chicago
Texas
- University of Texas at Austin - Austin
- University of Texas at San Antonio - San Antonio
Colorado
- University of Colorado - Aurora
Connecticut
- Yale University - New Haven
Maryland
- Gaelle Massoud - Baltimore
Michigan
- Wayne State University - Detroit
New York
- Columbia University - New York
Pennsylvania
- Pennsylvania State University - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2026-12 |
What NCT05444283 shows while recruiting
NCT05444283 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Recurrent Pregnancy Loss appearing as the primary indexed condition, and to 0 interventions.
NCT05444283 lists 10 locations in 8 states (Illinois, Texas, Colorado).
Frequently Asked Questions
What is clinical trial NCT05444283 about?
NCT05444283 is a clinical study titled "Genomic Predictors of Recurrent Pregnancy Loss". The overall goals of this proposal are to determine the genetic architecture of recurrent pregnancy loss (RPL) and to discover genomic predictors of RPL.
What is the current status of trial NCT05444283?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2021-09-01. Estimated completion is 2026-12.
What conditions does trial NCT05444283 study?
This clinical trial studies the following conditions: Recurrent Pregnancy Loss.
Who is sponsoring clinical trial NCT05444283?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05444283 being conducted?
This trial has 10 study locations across Colorado, Connecticut, Illinois, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Pregnancy Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI